Sermorelin.com Introduces Physician-Led Telehealth for Sermorelin Treatment Sheridan, United States - March 15, 2026 / ...

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Researchers analyzed nearly 8,000 patients stopping semaglutide or tirzepatide. Most patients maintained weight or continued losing weight after one year, often by restarting therapy, switching ...

As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24.

UAB researchers report that the oral drug TIX100 prevented weight regain after stopping semaglutide in preclinical studies.

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

TIX100 is a specific, orally available TXNIP inhibitor originally developed for its beta-cell protective effects in diabetes. It has received FDA Investigational New Drug approval in diabetes and ...

(Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive ...

GLP-1 receptor agonists have gained attention as medications to manage type 2 diabetes and obesity. Drugs such as semaglutide and tirzepatide help regulate blood sugar and reduce appetite, which can ...